[
  {
    "ts": null,
    "headline": "Merck: Cheap Stock, But Still Relying Heavily On Keytruda (Rating Upgrade)",
    "summary": "Merck: Cheap Stock, But Still Relying Heavily On Keytruda (Rating Upgrade)",
    "url": "https://finnhub.io/api/news?id=bde7b9cd3513ffe04737bc924142060e24a5f5b12c5ebadf97ad69cb654b23f2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751031371,
      "headline": "Merck: Cheap Stock, But Still Relying Heavily On Keytruda (Rating Upgrade)",
      "id": 135594505,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=bde7b9cd3513ffe04737bc924142060e24a5f5b12c5ebadf97ad69cb654b23f2"
    }
  },
  {
    "ts": null,
    "headline": "Cancer Vaccine (Preventative, Therapeutic) Market Research 2025 with Analyst Recommendations-Leveraging AI and Bioinformatics for Precision Development / Pursue Fast-Track and Orphan Drug Designations",
    "summary": "Explore the Global Cancer Vaccine Market's growth from $12.16 billion in 2024 to an expected $20.88 billion by 2031. Driven by innovations in immuno-oncology, the market is dominated by preventative and recombinant vaccines. Key players include Merck, Amgen, and Moderna. Asia Pacific sees fastest growth.Dublin, June 27, 2025 (GLOBE NEWSWIRE) -- The \"Cancer Vaccine Market (2025 Edition): Analysis By Type (Preventative, Therapeutic), By Technology Type, By Region, By Country: Market Insights and F",
    "url": "https://finnhub.io/api/news?id=501681acb583442180947cf8962a4d2e2b51d6cef9fad0b9a970248afed5f4fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751031300,
      "headline": "Cancer Vaccine (Preventative, Therapeutic) Market Research 2025 with Analyst Recommendations-Leveraging AI and Bioinformatics for Precision Development / Pursue Fast-Track and Orphan Drug Designations",
      "id": 135590979,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Explore the Global Cancer Vaccine Market's growth from $12.16 billion in 2024 to an expected $20.88 billion by 2031. Driven by innovations in immuno-oncology, the market is dominated by preventative and recombinant vaccines. Key players include Merck, Amgen, and Moderna. Asia Pacific sees fastest growth.Dublin, June 27, 2025 (GLOBE NEWSWIRE) -- The \"Cancer Vaccine Market (2025 Edition): Analysis By Type (Preventative, Therapeutic), By Technology Type, By Region, By Country: Market Insights and F",
      "url": "https://finnhub.io/api/news?id=501681acb583442180947cf8962a4d2e2b51d6cef9fad0b9a970248afed5f4fd"
    }
  },
  {
    "ts": null,
    "headline": "Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?",
    "summary": "TEM is scaling fast; Data and Services revenues soar 43%, fueled by big-name pharma and AI model deals.",
    "url": "https://finnhub.io/api/news?id=eb57022593860af3f8cefb7d3409d83c5db4567b94c5db1802bfaa713c57bd74",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751030100,
      "headline": "Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?",
      "id": 135590980,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "TEM is scaling fast; Data and Services revenues soar 43%, fueled by big-name pharma and AI model deals.",
      "url": "https://finnhub.io/api/news?id=eb57022593860af3f8cefb7d3409d83c5db4567b94c5db1802bfaa713c57bd74"
    }
  },
  {
    "ts": null,
    "headline": "Merck: receives ACIP recommendation for Enflonsia",
    "summary": "Merck announces that the CDC's Advisory Committee on Immunization Practices has voted in favor of recommending Enflonsia for the prevention of respiratory infections caused by RSV in infants under 8...",
    "url": "https://finnhub.io/api/news?id=acaa1cb4549185edaee43998cb32ebca86c1674a832d779a93723e78873cf8c5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751002677,
      "headline": "Merck: receives ACIP recommendation for Enflonsia",
      "id": 135587332,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announces that the CDC's Advisory Committee on Immunization Practices has voted in favor of recommending Enflonsia for the prevention of respiratory infections caused by RSV in infants under 8...",
      "url": "https://finnhub.io/api/news?id=acaa1cb4549185edaee43998cb32ebca86c1674a832d779a93723e78873cf8c5"
    }
  }
]